CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION Medford, N.Y., USA / Strasbourg, France – January 22,…
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA Chembio Diagnostic System, Inc. (Chembio), a wholly owned…
FOOD AND DRUG ADMINISTRATION AWARDS BREAKTHROUGH DEVICE STATUS TO THE DPP® SYPHILIS TnT ASSAY Medford, N.Y. USA / Strasbourg, France – July 29, 2025 – Chembio Diagnostic Systems, Inc., a…
Medford N.Y USA/Strasbourg France – June 17, 2025 – Chembio Diagnostic Systems, Inc., a subsidiary of Biosynex, developer and manufacturer of rapid diagnostic tests, announced today that the U.S. Food…
